Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma

Reviews on Recent Clinical Trials

Volumn 2, Issue 3, 2007, Pages 206-211

  Kasper, Bernd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Molecular targeted therapies; New treatment strategies; Soft tissue sarcoma; Therapy standards

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; AP 23573; BEVACIZUMAB; BROSTALLICIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; OBLIMERSEN; OXALIPLATIN; PAZOPANIB; PEMETREXED; PIOGLITAZONE; RAPAMYCIN; ROFECOXIB; SEMAXANIB; SORAFENIB; TEMSIROLIMUS; THALIDOMIDE; TRABECTEDIN; TROFOSFAMIDE; UNINDEXED DRUG; VORINOSTAT;

ADJUVANT THERAPY; ANGIOSARCOMA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; GENE REARRANGEMENT; GENETIC RISK; GYNECOLOGIC CANCER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTHERMIC THERAPY; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER CELL CARCINOMA; MOUTH PAIN; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; SYNOVIAL SARCOMA; UNSPECIFIED SIDE EFFECT; UTERUS SARCOMA;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL PROTOCOLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC FACTORS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; SARCOMA;

EID: 35248841104     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488707781662706     Document Type: Review

References (64)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001: 1841-91.
3. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91: 1914-26.
4. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993; 217: 72-7.
5. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997; 24: 504-14.
6. Smith AH, Pearce NE, Fisher DO. Soft tissue sarcoma and exposure to phenoxyherbicides and chlorophenols in New Zealand. J Nat Cancer Inst 1984; 73: 1111.
7. Levine EA. Prognostic factors in soft tissue sarcoma. Semin Surg Oncol 1999; 17.
8. Vorburger SA, Hunt KK. Experimental Approaches, in Pollock RE (ed). Soft Tissue Sarcomas. Hamilton, Ontario, BC Decker, Inc., 2002: 89-109.
9. Hieken TJ, Das Gupta TK. Mutant p53 expression: a marker of diminished survival in well-differentiated soft tissue sarcoma. Clin Cancer Res 1996; 2: 1391-5.
10. Pisters P. Staging and Prognosis, in Pollock RE (ed). American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas. Hamiliton, Ontario: BC Decker, Inc.; 2002: 80-8.
11. Standard-Options-Recommandations. Sarcome des Tissus Mous et Ostéosarcomes. Paris, France, Amette Blackwell, 1995; Vol 1, pp. 1-113.
12. Verweij J, Mouridsen HT, Nielsen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view. Crit Rev Oncol Hematol 1995; 20: 193-201.
13. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - Dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-84.
14. Saeter G, Alvegard TA, Monge OR, et al. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma: A Scandinavian Sarcoma Group phase II study. Eur J Cancer 1997; 33: 1551-8.
15. Jelic S, Kovcin V, Milanovic N, et al. Randomised study of highdose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997; 33: 220-5.
16. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 1998; 16: 1438-43.
17. Bui NB, Demaille MC, Chevreau C, et al. qMAID vs MAID + 25 % in adults with advanced soft tissue sarcoma (STS): First results of a randomized study of the FNCLCC Sarcoma Group. Proc Am Soc Clin Oncol 1998; 17: 517a (abstract 1991).
18. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000; 36: 61-7.
19. Frustaci S, Buonadonna A, Romanini A, et al. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors. Tumori 1999; 85: 229-33.
20. Demetri GD. Major developments in the understanding and treatment of soft-tissue sarcomas in adults. Curr Opin Oncol 1998; 10: 343-7.
21. Tierney JF. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997; 350: 1647-54.
22. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001; 19: 1238-47.
23. Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 2002; 25: 468-73.
24. Casali PG, Picci P. Adjuvant chemotherapy for soft tissue sarcoma. Curr Opin Oncol 2005; 17: 361-65.
25. Issels RD, Schlemmer M. Current trials and new aspects in soft tissue sarcoma of adults. Cancer Chemother Pharmacol 2002; 49: S4-S8.
26. Woll PJ, van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxcrubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised, phase III trial. Proc Am Soc Clin Oncol 2007; 25: 18S (abstract 10008).
27. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001; 19: 3203-9.
28. Issels RD, Lindner LH, Wust P, et al. Regional hyperthemia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade, soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised pros. Proc Am Soc Clin Oncol 2007; 25: 18S (abstract 10009).
29. Pezzi CM, Pollock RE, Evans HL, Lorigan JG, Pezzi TA, Benjamin RS, Romsdahl MM. Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 1990; 211: 476.
30. Connier JN, Pollock RE. Soft tissue sarcomas. Cancer J Clin 2004; 54: 94-109.
31. Reichardt P. High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 2002; 41: 157-67.
32. Kasper B, Lehnert T, Bernd L, et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004; 34: 37-41.
33. Kasper B, Ho AD, Egerer G. Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma? Oncology 2005; 68: 115-21.
34. Svancarova L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft tissue sarcomas: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38: 556-9.
35. Okuno S, Edmonson J, Mahoney M, et al. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002; 94: 3225-9.
36. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft-tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001; 19: 3483-9.
37. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-9.
38. Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006; 119:706-711. Erratum in: Int J Cancer 2007; 120: 450.
39. Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anti Cancer Res 2003; 23: 1899-901.
40. Reichardt P, Pink D, Tilgner J, Kretzschmar A, et al. Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis. Onkologie 2002; 25: 541-6.
41. Kasper B, Ho AD, Egerer G. A new therapeutic approach in patients with advanced sarcoma. Int J Clin Oncol 2005; 10: 438-40.
42. Balasubramanian L, Evens AM. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol 2006; 18: 354-9.
43. Yi-Shin Kuo D, Timmins P, Blaak SV, et al. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. Gynecol Oncol 2006; 100: 160-5.
44. D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas. J Clin Oncol 2005; 23: 7135-42.
45. Kuenen BC, Tabernero J, Baselga J, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003; 9: 1648-55.
46. Heymach JV, Desai J, Manola J, et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcoma. Clin Cancer Res 2004; 10: 5732-40.
47. Sleijfer S, Papai Z, Le Cesne A, et al. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS). EORTC 62043. Proc Am Soc Clin Oncol 2007; 25: 18S (abstract 10031).
48. Knight LA, Di Nicolantonio F, Whitehouse P, et al. The in vitro effect of gefitinib (Iressa) alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 2004; 23: 83.
49. Blay J, Le Cesne A, Whelan J, et al. Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. Proc Am Soc Clin Oncol 2006; 24: 18S (abstract 9517).
50. Bode B, Frigerio S, Behnke S, et al. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol 2006; 19: 541-7.
51. Joyner DE, Albritton KH, Bastar JD, Randall RL. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. J Orthop Res 2006; 24: 474-80.
52. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today 2005; 41: 773-84.
53. D'Adamo DR, Keohan ML, Schuetze S, et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). Proc Am Soc Clin Oncol 2007; 25: 18S (abstract 10001).
54. Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. Curr Opin Oncol 2006; 18: 360-2.
55. Chawla S, Tolcher A, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial. Proc Am Soc Clin Oncol 2007; 25: 18S (abstract 10076).
56. Rossi F, Ehlers I, Agosti V, et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 2006; 103: 12843-8.
57. Verweij J. Ecteinascidin-743 (ET-743): Early test or effective treatment in soft tissue sarcomas? J Clin Oncol 2005; 24: 5420-3.
58. Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006; 18: 347-53.
59. Grosso F, Forni C, Frapolli R, et al. Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. Proc Am Soc Clin Oncol 2007; 25: 18S (abstract 10000).
60. Blay JY, von Mehren M, Samuels BL, et al. Combination of trabectedin (T) and doxorubicin (D) for the treatment of patients with soft tissue sarcoma (STS): safety and efficacy analysis. Proc Am Soc Clin Oncol 2007; 25: 18S (abstract 10078).
61. Leahy MG, Ray-Coquard I, Verweij J, et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2007; 43: 308-15.
62. Misset JL, Gamelin E, Campone M, et al. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann Oncol 2004; 15: 1123-9.
63. D'Adamo DR, Scheu K, Singer S, et al. A phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. Proc Am Soc Clin Oncol 2006; 24: 18S (abstract 9523).
64. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923-31.